Genomics and precision medicine represent a fundamental shift in healthcare, moving from generalized treatment approaches to personalized interventions tailored to an individual's genetic makeup. Genomics, the study of an organism’s complete DNA sequence, enables deeper insights into disease predisposition, drug response, and therapeutic targets. Precision medicine builds upon these insights, leveraging genetic, environmental, and lifestyle data to optimize prevention and treatment strategies for each patient.
The foundation for modern precision medicine was laid by the Human Genome Project, an international effort that successfully mapped the entire human genome in 2003.1 This milestone drastically reduced the cost and time required for genetic sequencing, making genome-based diagnostics and therapies more accessible. Advances in sequencing technologies and computational biology have since accelerated the application of genomic data, allowing for the development of targeted therapies across multiple disease areas. In oncology, for instance, tumor profiling has led to breakthroughs in immunotherapy and biomarker-driven treatment selection. Similarly, pharmacogenomics has refined drug development, reducing adverse reactions and improving therapeutic efficacy.
This transformation marks a departure from the traditional one-size-fits-all model of medicine, where treatments are prescribed based on population-level data rather than individual variability. Historically, many therapies have been developed with broad efficacy in mind, often overlooking how genetic differences influence disease progression and drug metabolism. Genomics now provides the ability to stratify patients based on their unique molecular profiles, making treatment more precise and effective. The widespread adoption of precision medicine has the potential to enhance clinical outcomes, improve healthcare efficiency, and lower overall costs by reducing trial-and-error prescribing and hospitalizations due to adverse drug reactions.
With these advancements, a critical question emerges: How are genomics and precision medicine transforming healthcare today? Beyond their implications for disease treatment, their role extends to early detection, risk assessment, and even disease prevention. As researchers continue to refine genomic applications and integrate multi-omics approaches — including proteomics and metabolomics — precision medicine is poised to become an integral part of routine healthcare. However, challenges remain, particularly in terms of accessibility, ethical considerations, and the integration of genomic data into existing healthcare frameworks.
The Scientific Basis of Precision Medicine
At the core of precision medicine lies the ability to decode an individual’s genetic information and apply it to clinical decision-making. Advances in genomic sequencing have revolutionized the field, making personalized treatment strategies increasingly viable. These innovations are further enhanced by multi-omics integration, which incorporates layers of biological data, and artificial intelligence, which enables the rapid interpretation of complex genetic information.
Genomic sequencing has undergone dramatic improvements in both accuracy and affordability over the past two decades. The completion of the Human Genome Project initially set sequencing costs in the millions of dollars, but technological advancements, particularly next-generation sequencing (NGS), have brought the price of whole-genome sequencing to under $1,000 per individual.2,3 This cost reduction has allowed for large-scale genomic studies that provide insights into disease susceptibility, genetic mutations, and individualized therapeutic responses. With sequencing now more accessible, genomic medicine is transitioning from research-driven applications to routine clinical care, particularly in oncology, rare disease diagnosis, and prenatal testing.3
One of the most direct applications of genomic data in medicine is pharmacogenomics, which studies how genetic variations influence an individual’s response to medications. Small differences in DNA can affect how a person metabolizes drugs, leading to variations in efficacy and risk of adverse effects. Pharmacogenomic insights are already being used to guide drug dosing for anticoagulants, chemotherapy, and psychiatric medications, reducing trial-and-error prescribing and improving patient safety.4,5 The integration of pharmacogenomics into electronic health records (EHRs) and prescribing systems is a step toward making personalized medication regimens a standard of care.
Beyond genomics alone, the field of precision medicine increasingly relies on multi-omics integration — combining genomics with other molecular data such as proteomics (the study of proteins), metabolomics (metabolic profiles), and transcriptomics (gene expression patterns). Each of these omics layers provides additional context for understanding disease mechanisms and treatment responses. For instance, while genomics can identify a predisposition to disease, proteomics can reveal how that genetic predisposition manifests at the functional level. This comprehensive approach allows for more accurate biomarker discovery, enabling earlier disease detection and better therapeutic targeting.6,7
Artificial intelligence (AI) and machine learning (ML) have become essential tools in genomic medicine, particularly in managing the vast amounts of data generated by sequencing and multi-omics analyses. AI-driven models can identify patterns in genomic sequences that correlate with disease risk, predict treatment responses, and optimize clinical trial designs. These technologies have already shown promise in oncology, where ML algorithms analyze tumor genomics to match patients with the most effective targeted therapies. Additionally, AI is being applied to genomic variant interpretation, reducing the time required to identify pathogenic mutations and expediting rare disease diagnoses.7,8 As AI continues to evolve, it is expected to further enhance precision medicine by refining risk prediction models and enabling fully personalized treatment plans.
The convergence of these scientific advances — cost-effective sequencing, pharmacogenomics, multi-omics integration, and AI-driven analysis — has laid the groundwork for precision medicine to become a mainstream approach in healthcare. However, translating these innovations into widespread clinical use requires overcoming challenges related to data integration, regulatory frameworks, and equitable access.
Key Applications of Genomics in Medicine
The integration of genomics into medicine has significantly advanced the diagnosis, treatment, and prevention of diseases across multiple fields. By leveraging genomic insights, clinicians can develop highly targeted therapies, improve early disease detection, and personalize treatment regimens based on an individual’s genetic profile. From oncology to infectious disease management, genomics is reshaping medical practice and providing new pathways for improving patient outcomes.
Oncology: Redefining Cancer Treatment with Genomics
Cancer treatment has been transformed by genomic tumor profiling, which enables oncologists to match patients with therapies tailored to the genetic characteristics of their tumors. Targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies (mAbs), are designed to block specific molecular pathways driving tumor growth, improving efficacy while minimizing side effects.3,9 Immunotherapy, another major breakthrough, relies on genomic insights to identify tumor-specific mutations that make cancer cells more recognizable to the immune system. The success of immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapies illustrates the power of precision medicine in oncology.
Liquid biopsies represent another significant advancement in cancer care, providing a non-invasive method for detecting circulating tumor DNA (ctDNA) in the bloodstream. This approach allows for earlier cancer diagnosis, monitoring of treatment response, and detection of minimal residual disease following therapy.10 By eliminating the need for traditional tissue biopsies in certain contexts, liquid biopsies are improving patient comfort while enhancing the ability to track tumor evolution in real time.
Rare and Genetic Diseases: Expanding Diagnostic and Treatment Options
For rare genetic diseases, genomics has dramatically improved diagnostic accuracy and treatment development. Whole-genome sequencing (WGS) is increasingly used in neonatal and pediatric settings to identify genetic disorders early, allowing for timely interventions that can significantly alter disease trajectories.11,12 In cases where early diagnosis leads to appropriate management — such as dietary modifications for metabolic disorders like phenylketonuria — genomic medicine can prevent severe health complications.
Gene therapies have emerged as a transformative approach for previously untreatable genetic conditions. Techniques such as adeno-associated virus (AAV)-mediated gene therapy and CRISPR-based genome editing are enabling targeted correction of disease-causing mutations. Notable examples include gene therapies for spinal muscular atrophy (SMA) and inherited retinal diseases, which have restored function in affected individuals.9 As gene-editing technologies continue to advance, they hold the potential to provide durable and even curative treatments for a growing number of genetic disorders.
Cardiology: Precision Approaches to Cardiovascular Disease
Genomic research has identified numerous genetic risk factors for cardiovascular diseases, including hypertrophic cardiomyopathy, arrhythmias, and familial hypercholesterolemia.12,13 Understanding these genetic predispositions allows for early screening and preventive measures in at-risk individuals. Clinicians can use polygenic risk scores to stratify patients based on their likelihood of developing conditions like coronary artery disease, enabling more personalized monitoring and interventions.
In addition to risk assessment, pharmacogenomic insights are refining the treatment of cardiovascular conditions. Genetic variations influence individual responses to anticoagulants, statins, and antihypertensive drugs, guiding clinicians in selecting the most effective and safest medications for each patient.4 This personalized approach reduces the risk of adverse effects while optimizing therapeutic outcomes, moving away from the trial-and-error prescribing model that has historically characterized cardiovascular pharmacotherapy.
Neurology and Psychiatric Disorders: Unlocking the Genetic Basis of Brain Diseases
Neurological and psychiatric disorders, long considered complex and multifactorial, are increasingly understood through the lens of genomics. Research has identified genetic risk factors associated with Alzheimer’s disease, Parkinson’s disease, and schizophrenia, paving the way for earlier diagnosis and targeted interventions.8 In Alzheimer’s disease, for example, individuals carrying the APOE4 variant face a higher risk of developing the disease, informing screening strategies and preventive lifestyle recommendations.
Beyond risk assessment, precision medicine is revolutionizing neuropharmacology. By analyzing genetic variations that affect neurotransmitter pathways, researchers are developing more precise drug treatments for conditions like depression, bipolar disorder, and schizophrenia.7 Pharmacogenomics is already being used to guide antidepressant and antipsychotic selection, helping clinicians avoid medications that are unlikely to be effective based on a patient’s genetic makeup. As genomic insights continue to expand, the prospect of gene-based therapies for neurodegenerative and psychiatric conditions is becoming increasingly feasible.
Infectious Diseases and Public Health: Genomics in Disease Surveillance and Vaccine Development
Genomics is playing a critical role in infectious disease management, particularly in pathogen surveillance and outbreak response. WGS allows for the rapid identification of emerging viral and bacterial strains, enabling public health agencies to track disease spread, monitor mutations, and develop targeted containment strategies.14,15 During the COVID-19 pandemic, genomic surveillance was instrumental in identifying variants of concern and informing vaccine updates. Similarly, the application of genomics in antimicrobial resistance monitoring is helping to combat the growing threat of drug-resistant infections.
Vaccine development has also benefited from genomic insights, leading to the rapid design of mRNA vaccines and other targeted immunization strategies.16 By leveraging genomic information on viral proteins, researchers have been able to accelerate vaccine production and optimize immune responses. The success of mRNA-based COVID-19 vaccines has opened new possibilities for using genomic technology to develop vaccines for diseases such as influenza, HIV, and even cancer.
Global Adoption and Implementation Challenges
While genomics and precision medicine hold immense potential for transforming healthcare, their widespread adoption remains uneven across the globe. Governments, research institutions, and healthcare systems have initiated large-scale efforts to integrate genomic medicine into routine clinical practice, but significant barriers — ranging from healthcare disparities to ethical and regulatory concerns — continue to hinder progress. Addressing these challenges is critical to ensuring that precision medicine fulfills its promise of improving patient outcomes for all populations.
Major Initiatives Driving Genomic Medicine Integration
In the United Kingdom, the National Health Service (NHS) Genomics Strategy has positioned the country as a leader in integrating genomic medicine into standard healthcare. Through the Genomic Medicine Service, launched in 2018, the NHS provides WGS for rare disease and cancer patients, facilitating early diagnosis and targeted treatments. This initiative has also emphasized equitable access, ensuring that genomic medicine is incorporated into routine clinical workflows rather than remaining a niche service.13 The UK’s investment in a national genomic infrastructure, coupled with its commitment to ethical and regulatory oversight, serves as a model for other nations looking to implement similar programs.
In the United States, public health genomics initiatives have aimed to expand genomic testing and research while addressing regulatory and financial barriers to adoption. Programs such as the All of Us Research Program, launched by the National Institutes of Health (NIH), seek to build diverse genomic data sets that reflect the country’s demographic diversity. However, unlike the centralized NHS model, the fragmented nature of the U.S. healthcare system poses challenges in implementing widespread genomic screening and standardizing clinical applications.15,16 Many healthcare providers remain hesitant to integrate genomic medicine due to concerns about reimbursement, clinical utility, and the complexity of genomic data interpretation.
Beyond national programs, large-scale biobanks and global genomic databases play a pivotal role in making genomic medicine more accessible and advancing scientific discoveries. Biobanks such as the UK Biobank, the U.S.-based Million Veteran Program, and the FinnGen study collect and analyze genomic data from diverse populations, providing invaluable insights into genetic risk factors for various diseases. These initiatives contribute to the development of polygenic risk scores and improve the ability to predict disease susceptibility across different ethnic backgrounds.2 However, disparities in data representation persist, as many genomic databases are still disproportionately composed of European ancestry populations, limiting their applicability to other ethnic groups.
Challenges in Implementation
Despite these initiatives, several obstacles continue to impede the full-scale adoption of genomic medicine worldwide. One of the most pressing concerns is healthcare disparities, as access to genomic testing and precision therapies remains highly unequal. High-income countries have made substantial investments in genomic infrastructure, while many low- and middle-income countries (LMICs) lack the resources to implement widespread sequencing programs. Additionally, within countries, disparities exist along socioeconomic and racial lines, with underrepresented minorities often facing greater barriers to accessing genomic services.10,17 Addressing these inequities requires targeted efforts to increase diversity in genomic research and ensure that precision medicine does not exacerbate existing healthcare gaps.
Data privacy and security concerns present another significant barrier to genomic medicine adoption. As genomic data is inherently personal and sensitive, there is growing concern over how this information is stored, shared, and used. Ethical challenges include obtaining informed consent for data usage, ensuring proper anonymization, and preventing genetic discrimination in employment or insurance.5,18 Countries have adopted varying regulatory approaches, with the European Union’s General Data Protection Regulation (GDPR) enforcing strict privacy controls, while the U.S. Genetic Information Nondiscrimination Act (GINA) focuses on preventing genetic discrimination. However, gaps remain in global data governance, particularly regarding cross-border genomic data sharing and industry use of genetic information for commercial purposes.
Cost remains a fundamental challenge to genomic medicine implementation, even as sequencing prices have declined. While the cost of WGS has fallen to under $1,000 in many settings, additional expenses related to data analysis, clinical interpretation, and patient counseling can significantly increase the total cost of integrating genomics into healthcare.6 Many health insurance providers do not yet cover routine genomic testing, limiting patient access to precision diagnostics and treatments. Scaling up cost-effective genomic services and ensuring reimbursement pathways for clinically validated tests will be essential to expanding access.
Finally, physician adoption and genomic literacy represent a critical yet often overlooked barrier. Many healthcare providers lack formal training in genomics and feel unprepared to interpret complex genetic reports. Without proper education, clinicians may hesitate to incorporate genomic data into their decision-making or may misinterpret findings, leading to inappropriate recommendations.12,17 Efforts to integrate genomics into medical education, develop user-friendly clinical decision support tools, and provide ongoing training for physicians will be key to overcoming this challenge.
The Future of Precision Medicine
As genomic medicine continues to evolve, emerging technologies and policy developments are set to further transform healthcare. Advances in AI, gene-editing technologies, and direct-to-consumer (DTC) genetic testing are expanding the scope of precision medicine, while efforts to improve accessibility and regulatory frameworks aim to make these innovations widely available. Looking ahead, genomics will play an increasing role not only in treating disease but also in predicting and preventing it, marking a fundamental shift toward proactive healthcare.
Expanding AI-Driven Genomics
AI is becoming an indispensable tool in precision medicine, particularly in analyzing the massive amounts of data generated by genomic sequencing. ML algorithms can identify patterns in genetic variants, predict disease susceptibility, and guide treatment selection with unprecedented speed and accuracy. In oncology, AI-driven models are already being used to match cancer patients with the most effective targeted therapies based on their tumor’s genomic profile.7 Additionally, AI is refining polygenic risk scores, which assess an individual’s genetic predisposition to complex diseases like heart disease and diabetes by analyzing thousands of genetic markers. These risk assessments will enable earlier interventions and more personalized preventive strategies.
Beyond diagnostics, AI is playing a crucial role in drug discovery and development. By predicting how genetic mutations alter protein structures and cellular pathways, AI can accelerate the identification of promising drug candidates. This approach has the potential to reduce the time and cost associated with bringing new therapies to market, particularly for rare and complex diseases where traditional drug development pipelines have been less efficient.7
CRISPR and Gene-Editing Advancements
Gene-editing technologies, particularly CRISPR-Cas9, hold the potential to revolutionize the treatment of genetic diseases. CRISPR enables precise modifications to DNA, allowing scientists to correct disease-causing mutations or introduce protective genetic changes. While early applications of CRISPR have focused on rare monogenic disorders, such as sickle cell disease and beta-thalassemia, researchers are now exploring its potential for treating more complex conditions, including certain forms of cancer and neurodegenerative diseases.9
Recent advancements in gene-editing techniques, such as base editing and prime editing, offer even greater precision and fewer unintended genetic modifications. These next-generation tools are expanding the possibilities of genomic medicine, paving the way for safe and effective gene therapies that could provide long-lasting or even curative treatments. However, the widespread clinical adoption of gene-editing technologies will require continued research to address safety concerns, ethical considerations, and regulatory oversight.
Expansion of DTC Genetic Testing
The rise of DTC genetic testing has made genomic insights more accessible to the public. Companies offering at-home DNA tests provide consumers with information about ancestry, carrier status for genetic diseases, and even potential health risks based on genetic predisposition. While these tests have increased awareness of genomic medicine, they also raise concerns about accuracy, misinterpretation of results, and data privacy.5
Unlike clinical genomic testing, which is conducted under the supervision of healthcare professionals, many DTC tests provide results without medical guidance, leading to potential misinterpretation by consumers. False positives or ambiguous findings can cause unnecessary anxiety or lead individuals to make uninformed health decisions. Additionally, concerns over genetic data security and the commercial use of consumer DNA by testing companies have prompted calls for stricter regulations. Moving forward, the challenge will be to strike a balance between empowering individuals with genetic knowledge and ensuring that such information is used responsibly.
Precision Prevention: Shifting Toward Proactive Healthcare
While much of precision medicine has focused on treating disease, its future lies in precision prevention — leveraging genomic insights to predict and mitigate disease risk before symptoms arise. Advances in polygenic risk scoring and predictive modeling are making it possible to identify individuals at higher risk for conditions such as cardiovascular disease, diabetes, and certain cancers, enabling earlier interventions through lifestyle modifications, targeted screenings, and personalized pharmacological approaches.13,16
For example, individuals identified as having a genetic predisposition to breast cancer due to BRCA1 or BRCA2 mutations can take proactive measures, such as increased surveillance or preventive treatments, significantly reducing their risk. Similarly, pharmacogenomic screening can identify patients who may experience adverse drug reactions before they begin a new medication, improving both safety and efficacy. As the field progresses, integrating genomic risk assessments into routine healthcare could shift medicine from a reactive model — treating diseases after they develop — to a proactive one focused on early detection and prevention.
Global Accessibility and Policy Evolution
As precision medicine becomes more advanced, ensuring global accessibility remains a major challenge. Many LMICs lack the infrastructure to implement genomic testing, leading to disparities in who can benefit from these innovations. While some international initiatives, such as the World Health Organization’s Genomics Strategy, aim to promote equitable access, financial and logistical barriers continue to limit the widespread adoption of genomic medicine in under-resourced regions.15
Governments are playing a critical role in shaping the regulatory and policy landscape for genomic healthcare. Countries with established national genomic strategies, such as the UK and Finland, are leading the way in integrating precision medicine into public healthcare systems. However, varying regulations across countries complicate international genomic research collaboration and data sharing. Standardizing guidelines for genomic privacy, ethical considerations, and reimbursement policies will be essential for advancing precision medicine on a global scale.
As policymakers work to address these challenges, future genomic healthcare models will need to prioritize both scientific innovation and equitable implementation. Ensuring that precision medicine reaches diverse populations, developing global frameworks for ethical genomic data use, and integrating AI-driven technologies responsibly will define the next era of genomic medicine.
The coming years will determine how successfully precision medicine transitions from a cutting-edge innovation to a universally accessible standard of care. While challenges remain, the continued convergence of genomics, AI, and gene-editing technologies promises a future where healthcare is not only more effective but also more personalized and preventive than ever before.
Shaping the Future of Healthcare Using Genomics
Genomics is fundamentally reshaping healthcare by making medicine more precise, predictive, and personalized. The ability to analyze an individual’s genetic information and tailor medical interventions accordingly has already led to significant advancements in disease diagnosis, targeted treatments, and early risk detection. As genomic sequencing becomes more affordable and widely available, its impact on healthcare continues to expand, moving beyond specialized applications to become an integral component of routine clinical practice.17
Despite the remarkable progress, challenges remain in ensuring the full-scale adoption of precision medicine. Ethical concerns surrounding data privacy, disparities in access to genomic services, and the need for greater physician education all present barriers to widespread implementation. However, rapid advancements in sequencing technologies, artificial intelligence, and gene-editing techniques are accelerating the adoption of genomic medicine, making personalized treatments more accessible and effective than ever before.3,7 AI-driven analytics are streamlining genomic data interpretation, while gene therapies and CRISPR-based interventions hold the promise of curative treatments for genetic disorders that were once considered untreatable.
Looking ahead, the future of genomic medicine will depend on a commitment to equitable access, ethical oversight, and the integration of multi-omics and AI-driven diagnostics into standard healthcare workflows. Policymakers and healthcare providers must work collaboratively to ensure that genomic innovations are available to all patients, regardless of geographic or socioeconomic barriers. Establishing global frameworks for ethical genomic data use, expanding genomic literacy among clinicians, and fostering responsible AI applications in medicine will be critical in shaping the next era of precision healthcare.13,18
While challenges remain, the trajectory of genomic medicine is clear: it is poised to transform healthcare by shifting the focus from disease treatment to early detection and prevention, ultimately leading to more efficient, effective, and individualized care. With continued investment in research, infrastructure, and policy development, precision medicine has the potential to become a universal standard, improving health outcomes for populations around the world.
Our parent company, That’s Nice, is committed to supporting the companies and innovators driving the next wave of pharma and biotech innovation. To celebrate That’s Nice’s 30th anniversary, Pharma’s Almanac is diving into 30 groundbreaking advancements, trends, and breakthroughs that have shaped the life sciences, highlighting the industry-defining milestones our agency has had the pleasure of growing alongside. Here’s to 30 years of innovation and the future ahead!
References
1. International Human Genome Sequencing Consortium. “Initial sequencing and analysis of the human genome.” Nature. 409:860–921 (2001).
2. DuBois, James M, et al. “Attitudes toward genomics and precision medicine.” J. Clin. Transl. Sci. 5: e120 (2021).
3. Passaro, Antonio, et al. “Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.” Cell. 187: 1617–1635 (2024).
4. Peck, Richard W. “Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient.” Annual Review of Pharmacology and Toxicology. 58: 105-122 (2018).
5. Khoury, Muin J, et al. “Health equity in the implementation of genomics and precision medicine: A public health imperative.” Genetics in Medicine. 24: 1630–1639 (2022).
6. Strianese, Oriana, et al. “Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease.” Genes. 11: 747 (2020).
7. Abdelhalim, Habiba, et al. “Artificial Intelligence, Healthcare, Clinical Genomics, and Pharmacogenomics Approaches in Precision Medicine.” Front. Genet. 5 Jul. 2022.
8. Evans, William, et al. “Precision Medicine—Are We There Yet? A Narrative Review of Precision Medicine’s Applicability in Primary Care.” J. Pers. Med. 14: 418 (2024).
9. Marques, Lara, et al. “Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.” Pharmaceutics. 16: 332 (2024).
10. “PFMG2025–integrating genomic medicine into the national healthcare system in France.” The Lancet. 50: 101183 (2025).
11. Al-Dewik, Nader and M Walid Qoronfleh. “Genomics and Precision Medicine: Molecular Diagnostics Innovations Shaping the Future of Healthcare in Qatar.” Advances in Public Health. 19 Mar. 2019.
12. Singh, Rama S and Bhagwati P Gupta. “Genes and genomes and unnecessary complexity in precision medicine.” npj Genomic Medicine. 5: 21 (2020).
13. Bains, Manpreet, et al. “Ethnic inequities in genomics and precision medicine.” NHS Race and Health Observatory. Jun. 2024.
14. Doll, Bruce, et al. “Precision Medicine—A Demand Signal for Genomics Education.” Military Medicine. 187(Suppl1): 40–46 (2021).
15. Khoury, Muin J, et al. “From public health genomics to precision public health: a 20-year journey.” Genet. Med. 20: 574–582 (2019).
16. Khoury, Muin J and Kathryn E Holt. “The impact of genomics on precision public health: beyond the pandemic.” Genome Medicine. 13: 67 (2021).
17. Khoury, Muin J, et al. “Genomics and Precision Medicine 2021: Progress in Implementation, A Focus on Health Equity, and a New Public Health Initiative.” Centers for Disease Control and Prevention. 17 Dec. 2021.
18. Sahan, Kate, et al. “Ethical preparedness in genomic medicine: how NHS clinical scientists navigate ethical issues.” Journal of Medical Ethics. 50: 532–533 (2024).